

## Ad hoc release

Ad-hoc Release pursuant to Section 17 of the Market Abuse Regulation  
(Marktmissbrauchsverordnung)

### **Biofrontera AG and Maruho Initiate Joint Project to Explore Development Opportunities**

Leverkusen, Germany, July 13, 2016 – Biofrontera AG (FSE: B8F), the specialist in sun-induced skin cancer treatment, today announced that Biofrontera have signed an agreement with Maruho Co., Ltd., “Maruho”, a Japanese pharmaceutical company specializing in dermatology, to explore opportunities to co-develop new pharmaceutical products based on Biofrontera’s proprietary nanoemulsion technology.

Ameluz<sup>®</sup>, Biofrontera’s lead product which recently gained U.S. FDA approval, was developed through a similar strategy of the company’s proprietary nanoemulsion technology. Through the process, the active ingredient was stabilized and its skin penetration capability was enhanced to increase clinical efficacy.

Under the terms of the agreement, Maruho will finance all costs associated with this exploratory research of new products. It is currently planned for Maruho to own of any successfully developed products and for Biofrontera to be able to commercialize them in Europe.

The relationship between Biofrontera and Maruho was initiated in March 2013 when Maruho’s German subsidiary, Maruho Deutschland GmbH, initially invested in Biofrontera. In February 2014, following a second investment, Maruho issued an announcement according to section 27a Abs. 1 of the German Securities’ Trading Act and informed Biofrontera regarding its intentions to become a strategic partner.

Ameluz<sup>®</sup> is currently Biofrontera’s only pharmaceutical product on the market and the company remains focused on its sales and marketing efforts in Europe and the United States. With this agreement, Maruho and Biofrontera aim to enhance the company’s product portfolio and drive long-term revenue growth.

Leverkusen, July 13, 2016

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

## Ad hoc release

ISIN: DE0006046113

WKN: 604611

contact: Biofrontera AG

Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

e-mail: [press@biofrontera.com](mailto:press@biofrontera.com)